Linked Life Data

18525302

Source:http://linkedlifedata.com/resource/pubmed/id/18525302

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-6-5
pubmed:abstractText
Treatments for refractory metastatic renal cell cancer (RCC) are limited. Oral lenalidomide, a thalidomide-based drug having enhanced immunomodulatory and antiangiogenic properties and reduced toxicity, was evaluated for safety and efficacy in this setting.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1537-453X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
244-9
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Lenalidomide therapy for metastatic renal cell carcinoma.
pubmed:affiliation
Genitourinary Oncology Program, Methodist Hospital Research Institute, Houston, TX 77030, USA. ramato@tmh.tmc.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II